Colorectal clinical trials: what is on the horizon?

被引：1

作者：

Ahn, Daniel H. ^{[1
]}

Goldberg, Richard M. ^{[1
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Med Oncol, 460 W 10th Ave, Columbus, OH 43210 USA

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 04期

关键词：

colorectal cancer; immunotherapy; next-generation sequencing; targeted therapy; WILD-TYPE KRAS; MICROSATELLITE INSTABILITY; BRAF MUTATION; OPEN-LABEL; ACQUIRED-RESISTANCE; GENE AMPLIFICATION; CANCER STATISTICS; PLUS IRINOTECAN; RAS MUTATIONS; SOLID TUMORS;

D O I：

10.2217/fon.15.327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

引用

页码：525 / 531

页数：7

共 65 条

[41] Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival [J].

Osako, T ;

Miyahara, M ;

Uchino, S ;

Inomata, M ;

Kitano, S ;

Kobayashi, M .

ONCOLOGY, 1998, 55 (06) :548-555

[42] Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR [J].

Prahallad, Anirudh ;

Sun, Chong ;

Huang, Sidong ;

Di Nicolantonio, Federica ;

Salazar, Ramon ;

Zecchin, Davide ;

Beijersbergen, Roderick L. ;

Bardelli, Alberto ;

Bernards, Rene .

NATURE, 2012, 483 (7387) :100-U146

[43] Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study [J].

Price, Timothy J. ;

Peeters, Marc ;

Kim, Tae Won ;

Li, Jin ;

Cascinu, Stefano ;

Ruff, Paul ;

Suresh, Atilli Satya ;

Thomas, Anne ;

Tjulandin, Sergei ;

Zhang, Kathy ;

Murugappan, Swaminathan ;

Sidhu, Roger .

LANCET ONCOLOGY, 2014, 15 (06) :569-579

[44] Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer [J].

Price, Timothy J. ;

Hardingham, Jennifer E. ;

Lee, Chee K. ;

Weickhardt, Andrew ;

Townsend, Amanda R. ;

Wrin, Joseph W. ;

Chua, Ann ;

Shivasami, Aravind ;

Cummins, Michelle M. ;

Murone, Carmel ;

Tebbutt, Niall C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) :2675-2682

[45] REOVIRUS INFECTIONS IN HUMAN VOLUNTEERS [J].

ROSEN, L ;

SPICKARD, A ;

EVANS, HE .

AMERICAN JOURNAL OF HYGIENE, 1963, 77 (01) :29-&

[46] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study [J].

Saltz, Leonard B. ;

Clarke, Stephen ;

Diaz-Rubio, Eduardo ;

Scheithauer, Werner ;

Figer, Arie ;

Wong, Ralph ;

Koski, Sheryl ;

Lichinitser, Mikhail ;

Yang, Tsai-Shen ;

Rivera, Fernando ;

Couture, Felix ;

Sirzen, Florin ;

Cassidy, Jim .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2013-2019

[47] Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers [J].

Samowitz, WS ;

Sweeney, C ;

Herrick, J ;

Albertsen, H ;

Levin, TR ;

Murtaugh, MA ;

Wolff, RK ;

Slattery, ML .

CANCER RESEARCH, 2005, 65 (14) :6063-6070

[48]

Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]

[49] Cancer Statistics, 2014 [J].

Siegel, Rebecca ;

Ma, Jiemin ;

Zou, Zhaohui ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (01) :9-29

[50]

Smyrk TC, 2001, CANCER, V91, P2417, DOI 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.3.CO

← 1 2 3 4 5 6 7 →